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ABSTRACT – Purpose. Experimental autoimmune myocarditis (EAM) in rats is an animal model of 
human giant cell myocarditis and post-myocarditis dilated cardiomyopathy. The pathogenesis of EAM has 
not been elucidated, but there is accumulating evidence that cytokines secreted from 
monocytes/macrophages and T cells play a crucial role in the induction and progression of disease. 
Flavonoids are a large group of polyphenolic compounds abundantly present in the human diet, which 
scavenge oxygen radicals and have anti-inflammatory activities. Having in mind in vivo beneficial effects of 
flavonoid quercetin in different animal models of immunoinflammatory diseases such as experimental 
autoimmune encephalomyelitis and adjuvant arthritis, on the one side, and its in vitro suppressive effect on 
production of tumor necrosis factor–alpha (TNF- on the other side, we investigated the effects of 
quercetin on EAM in rats. Methods. Myocarditis was induced in Dark Agouti (DA) rats by injection of 
porcine cardiac myosin  and quercetin at doses of 10 or 20 mg/kg was orally administered from days 0 to 21 
after induction of disease. The severity of myocarditis was evaluated by determination of heart weight/body 
weight ratio (Hw/Bw) and histopathological examination of hearts. The levels of cytokines (TNF-, IL-12, 
IL-17 and IL-10) in serum and lymph node cells (LNC) culture supernatants were measured by ELISA. 
Results. The rats treated with 20 mg/kg of quercetin had significantly decreased incidence of EAM, Hw/Bw, 
macroscopic and microscopic scores of hearts. Further, in EAM rats treated with quercetin levels of TNF- 
and IL-17 were significantly lower, while the level of IL-10 was significantly higher both in serum and 
culture supernatants of LNC stimulated with concanavalin A compared with vehicle-treated animals. 
Conclusions. The present study suggests that quercetin ameliorates EAM, at least in part, by interfering 





Myocarditis and its sequela, dilated 
cardiomyopathy (DCM), are the major causes of 
heart failure (1, 2). Myocarditis, inflammation of 
the heart, is defined pathologically as 
mononuclear or mixed cellular infiltration 
associated with myocyte necrosis and 
degeneration in the presence or absence of 
fibrosis (3). At present, there is no universally 
accepted effective therapy for myocarditis, and 
therapeutic strategy is mostly directed to 
management of symptoms and complications. 
Autoimmunity has been hypothesized to play 
a role in the pathogenesis of human myocarditis 
and DCM (4), however, this issue is incompletely 
understood. In animal models autoimmune 
myocarditis/DCM can be initiated by a viral 
infection or by immunization with heart-specific 
autoantigens (5). 
Rat experimental autoimmune myocarditis 
(EAM), an animal model of human giant cell 
myocarditis and DCM, may be elicited by 
immunization with cardiac myosin or cardiac 
myosin peptides. In Lewis and Dark Agouti (DA) 
rats EAM is characterized by severe myocardial 
damage with a peak of inflammation in the heart 
around day 21 after immunization (6, 7). The 
pathogenesis of EAM has not been elucidated, but 
there is compelling evidence suggesting that the 
cytokines secreted from both 
monocytes/macrophages and T cells are involved 
in the induction and resolution of EAM. Th1 type 
cytokines (IL-2 and IFN-) and proinflammatory 
cytokines (IL-1 and TNF-) have been detected 
only in the inflammatory phase, while the 
production of Th2 cytokines (IL-10 and TGF-) 
has been found in the recovery phase (8). 
Interleukin-12 (IL-12), which is produced mainly 
by antigen-presenting cells and exerts potent 
proinflammatory effect by stimulating Th1 
response, has been suggested to play a key role in 
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Recently, it has been reported that IL-23, rather 
than IL-12, is responsible for inflammatory heart 
disease, however, IL-23 and IL-12 have 
redundant activities in priming and expansion of 
autoreactive cells (10). IL-23 has been implicated 
in the development of a new population of CD4+ 
cells termed Th17 (11), which produce IL-17, 
proinflammatory cytokine that activates T cells 
and other immune cells to produce a variety of 
cytokines, chemokines and cell adhesion 
molecules (12). Th17 cells have been shown to 
exert a pathogenic role in the development of 
EAM (10, 13, 14). 
Flavonoids are a large group of polyphenolic 
compounds abundantly present in certain 
vegetables, fruits, seeds and beverages (e.g. tea 
and wine) (15). Dietary intake rich in these 
compounds has been suggested to decrease the 
risk of cardiovascular disease and cancer (16) and 
reduce the incidence of cerebrovascular disease in 
humans (17). The beneficial effects of flavonoids, 
including quercetin, have been attributed to their 
anti-oxidant and anti-inflammatory properties. 
Several reports have suggested that a variety 
diseases associated with oxidative stress and 
inflammatory diseases may be beneficially 
influenced by flavonoids (16, 18-22). The anti-
inflammatory activity of quercetin has been 
reported in an animal model of arthritis (19). 
Interestingly, in experimental autoimmune 
encephalomyelitis (EAE), opposite effects of 
quercetin have been reported. Hendriks et al. 
found that quercetin suppresses EAE in rats and 
prevents monocyte infiltration into the CNS (23), 
while Verbeek et al. showed that quercetin fails to 
beneficially influence the course of EAE in mice, 
but, instead, suppresses recovery from acute 
inflammatory damage (22). Although the 
mechanisms of action and anti-inflammatory 
effects of quercetin are not yet fully elucidated, it 
has been reported that quercetin inhibits 
production and gene expression of TNF-α by 
human peripheral blood mononuclear cells and 
murine macrophages via modulation of NF-κB 
and IκB (24, 25). Quercetin also modulates nitric 
oxide metabolism in stimulated macrophages 
(26). 
Having in mind the beneficial effects of 
quercetin in animal models of 
immunoinflammatory diseases such as EAE and 
adjuvant arthritis on the one side, and its in vitro 
suppressive effects on production of 
proinflammatory cytokines, on the other side, we 
investigated whether quercetin could ameliorate 
EAM in rats. To our knowledge it is for the first 





Experimental animals and immunization 
Seven-week-old male Dark Agouti (DA) rats, 
weighing 190-220g, were purchased from the 
Military Medical Academy Animal House, 
Belgrade, housed in polyethylene cages 
containing sterilized wood shavings and given 
rodent chow and tap water ad libitum. 
Purified porcine cardiac myosin (Sigma 
Chemical Co., St.Louis, MO, USA) was dissolved 
in 0,01 M phosphate-buffered saline (PBS) and 
emulsified with an equal volume of complete 
Freund´s adjuvant (FCA) (Difco, Sparks, MD, 
USA) supplemented with Mycobacterium 
tuberculosis H37RA (Difco) at a concentration of 
10 mg/ml. On days 0 and 7, rats were injected in 
the footpads subcutaneously with 0,1 ml of 
emulsion, yielding an immunizing dose of 1,0 
mg/body of cardiac myosin per rat (27, 28). 
Control rats were injected with PBS in FCA. No 
rat died prior to day 21. 
All experimental procedures and protocols 
conformed to institutional guidelines for the care 
and use of animals in research No 2/09 (Ethics 
Committee of the Faculty of Pharmacy, Belgrade, 
Serbia).  
 
Treatment with quercetin 
Effects of quercetin on EAM were evaluated 
using two different doses of quercetin: 10 and 20 
mg per kilogram of body weight (mg/kg bw). 
Five experimental groups (A-E) were created. 
Groups A-C consisted of 10 rats immunized with 
myosin/FCA (EAM rats), groups D and E 
consisted of 6 rats injected with PBS in FCA 
(control groups). Groups A and B were treated 
per os during 21 days (starting from day 0 to day 
20) with 10 and 20 mg of quercetin (Sigma, St. 
Louis MO, USA) per kilogram of body weight, 
respectively. Group C received per os vehicle. 
Group D was treated with quercetin (20 mg/kg 
bw) in parallel with the diseased protocol, while 
group E received vehicle.  
 
Histopathology 
All rats were sacrificed under ether anesthesia on 
day 21 after immunization. Blood samples were 
obtained from inferior vena cava. After 
thoracotomy the hearts were rinsed with saline 
and macroscopic findings of hearts were 
classified into four grades according to the 






following criteria: 0 (normal appearance), 1 (focal 
discolored area), 2 (multiple or diffuse discolored 
areas not exceeding 1/3 of the heart), 3 (diffuse 
discolored areas not exceeding 2/3 of the heart) 
and 4 (diffuse discolored areas exceeding 2/3 of 
the heart). Subsequently, heart weight without 
atria and the body weight were measured, and the 
ratio of heart weight to body weight (Hw/Bw) 
was calculated. The heart was fixed in 10% 
buffered formalin, embedded in paraffin, 
sectioned into 4µm slices (five transverse sections 
per heart ) and stained with hematoxylin eosin. 
Two observers (one pathologist) scored the 
histopathological scores blindly. Microscopic 
findings were graded: 0 (normal), 1 (lesion extent 
not exceeding 1% of a transverse section), 2 (not 
exceeding 10%), 3 (not exceeding 50%), and 4 
(exceeding 50%). We measured the lesion area 




Lymph node cells (LNC) were harvested and 
single-cell suspensions were obtained by passing 
through a stainless steel mesh screen. Cells were 
suspended in RPMI 1640 (Sigma-Aldrich Chemie 
Gmb) supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (Gibco, Grand Island, N.Y. 
USA), 2 mM L-glutamine (Serva, Heidelberg, 
Germany), 1 mM sodium pyruvate (Serva), 100 
units/ml penicillin (ICN, Costa Mesa, CA, USA) 
and 100 μg/ml streptomycin (ICN). Cells were 
seeded in 96-well plates (1x106/ml; Nunc A/S) 
and stimulated with 2,5 μg/ml of concanavalin A 
(ConA; Pharmacia, Sweden) for cytokine 
production. All cultures were run in triplicate. 
Cell culture supernatants were collected after 72 h 
of stimulation and were frozen until analyzed.   
 
Cytokine measurement  
On day 21 after immunization cytokines (TNF-, 
IL-12, IL-17 and IL-10) were measured in serum 
and culture supernatants using commerially 
available ELISA kits (for TNF- and IL-10: 
Quantikine ELISA kit; R&D Systems, 
Minneapolis, USA; for IL-12 (p70): BioSource 
International, Camarillo, CA, USA; for IL-17: 
Biosciences, San Diego, CA, USA) according to 
manufacturer's instructions. Detection limits were 
5 pg/ml for TNF-, 2 pg/ml for IL-17, 2,5 pg/ml 




Data are presented as mean ± standard deviation 
(SD). The Mann-Whitney U test was applied 
using the program SPSS11.5 for Windows (SPSS, 
Inc., Chicago, IL) for comparison of data between 





Effects of quercetin on clinical course of EAM 
and histological parameters  
The potential beneficial effects of quercetin on 
EAM were evaluated by using two doses of 
quercetin, 10 and 20 mg/kg bw. These doses are 
lower than those previously tested in animal 
studies (23, 29) and more correspond to doses 
used in human subjects (30). EAM animals 
(groups A and B) were treated per os with 
quercetin from day 0 to day 20 after induction of 
disease, and on day 21 all animals were 
sacrificed.  
The Hw/Bw ratio was increased in vehicle-
treated EAM animals (group C) compared with 
that in normal control group (group E). In the 
vehicle-treated animals hearts were markedly 
enlarged and contained diffuse grayish areas 
(mean macroscopic score 1.6 ± 0.5). 
Microscopically, inflammatory lesions composed 
of marked infiltration by mononuclear cells were 
observed (Table 1, Figure 1b). However, 
treatment with a higher dose of quercetin (20 
mg/kg bw, group B) suppressed the development 
of EAM. Myocarditis was observed in only 50% 
of these animals. Within this treatment group, 
Hw/Bw ratio, macroscopic and microscopic 
scores were significantly lower in comparison 
with those in vehicle-treated EAM rats (Table 1).  
Histological examination revealed mild 
inflammation consisting of sporadic inflammatory 
foci scattered between the muscle fibers (Figure 
1c). Treatment with 10 mg/kg bw of quercetin 
(group A) was not effective in reducing the 
incidence and severity of the disease (Table 1). 
The ratio of the myocarditis-affected area in 
group A was smaller than that in vehicle-treated 
EAM rats (group C), however, the difference did 















Figure 1. The treatment of EAM rats with 20 mg/kg of quercetin reduced mononuclear cell infiltration in myocardium. 
(a) The heart from a control animal which was injected with PBS in FCA appears normal. (b) The heart from a rat with 
myocarditis treated with vehicle. Inflammatory infiltrate is shown. (c) Representative histopathology of a rat with 
myocarditis treated from days 0 to 21 with 20 mg/kg and (d) 10 mg/kg of quercetin. Hematoxylin and eosin staining, 
original magnification: x160. 
 
 
Effects of quercetin on serum levels of 
cytokines  
To determine if quercetin treatment alters serum 
levels of TNF-α, IL-12, IL-17 and IL-10, serum 
was isolated and then analyzed by ELISA. As 
shown in Figure 2, serum level of TNF-α was 
markedly decreased in EAM animals treated with 
20 mg/kg bw of quercetin (group B) compared 
with vehicle- treated EAM rats (group C). Since 
in our preliminary study the serum level of IL-10 
was below the limit of the sensitivity of the assay 
(10 pg/ml), on day 21 after immunization five 
animals from each group were injected i.p. with 
1mg/kg bw of lipopolysaccharide (LPS) from 
E.coli (serotype O55:B5, Sigma), and 4h later 
blood samples were collected. Injection of LPS 
provokes the in vivo activation of macrophages, 
which within 2-6h leads to a release of IL-10 into 
the circulation (31). Compared with the vehicle-
treated group, there was significant increase of the 
level of IL-10 in 20 mg/kg bw quercetin-treated 
group (Figure 2). No significant differences in the 
serum concentrations of IL-12 and IL-17 were 
observed between vehicle- and quercetin-treated 
EAM rats (Figure 2).  
 
Effects of quercetin on production of cytokines 
in the supernatants of LNC  
The levels of TNF- and IL-17 in LNC culture 
supernatants were significantly decreased in EAM 
animals treated with 20 mg/kg bw of quercetin 
(group B) compared with vehicle-treated EAM 
animals (group C). However, production of IL-10 
was significantly increased in both 10 and 20 
mg/kg bw quercetin-treated groups. There was no 
difference in concentration of IL-12 between 
quercetin- and vehicle-treated EAM animals 
(Figure 3).  









A: Myosin/FCA + quercetin 10 mg/kg (0-20 day)  
B: Myosin/FCA + quercetin 20 mg/kg (0-20 day) 
C: Myosin/FCA + vehicle  







3.43 ± 0.18 
3.23 ± 0.23* 
3.50 ± 0.15 
3.18 ± 0.20 
3.00 ± 0.30
1.2±0.5 
0.8 ± 0.4** 





2.4 ± 0.5 
0 
0
Values are expressed as the mean ± S.D. and are significantly different from those of the vehicle-treated EAM rats 
(group C). * p< 0.05, ** p< 0.01.  








Figure 2. The effect of quercetin on TNF-, IL-12, IL-17 and IL-10 serum levels. Animals immunized with 
myosin/FCA (EAM rats) were treated with vehicle or quercetin (10 and 20 mg/kg) from days 0 to 21 after induction of 
myocarditis. On day 21 serum levels of TNF-,IL-12, IL-17 and IL-10 were measured using ELISA. Results are 
expressed as mean values ± SD. For statistical analysis each group was compared to vehicle-treated rats by Mann-




Figure 3. The effect of quercetin on production of TNF-, IL-12, IL-17 and IL-10 in culture supernatants of ConA- 
primed lymph node cells. Lymph node cells isolated from vehicle- and quercetin-treated EAM rats on day 21 after 
induction of disease were grown in vitro for 48h with Con-A (2.5 g/ml) and the production of TNF-, IL-12, IL-17 
and IL-10 was subsequently measured in cell culture supernatants by ELISA. Data are expressed as mean values ± SD, 





Treatment of acute myocarditis in humans 
remains a major clinical problem (32). Because 
evidence has accumulated that autoimmune 
mechanisms play a pivotal role in myocarditis and 
DCM, immunomodulatory therapy has attracted a 
great deal of attention. The current study has 
aimed to investigate the effects of quercetin, 
preselected from its ability to inhibit TNF- 
production in vitro, on experimental autoimmune 
myocarditis in rats. In animal models, quercetin 






was found to be effective in T cell-mediated 
autoimmune diseases such as adjuvant arthritis 
and experimental autoimmune encephalomyelitis 
(19, 23). 
We found that daily administration of 20 mg/ 
kg bw of quercetin for 3 weeks ameliorated 
autoimmune myocarditis significantly. In 
quercetin-treated group markers reflecting the 
severity of myocarditis including the Hw/Bw 
ratio, macroscopic and microscopic scores were 
lower than in the vehicle-treated group.  
The pathogenic mechanism of the EAM 
model involves three sequential processes. In the 
first step autoreactive T cells are activated and 
expanded by a fragment of cardiac myosin. The 
second step is recruitment of activated T cells to 
the target organ, and the third step appears to be 
effector-target interaction. Cells causing 
inflammation consist primarily of macrophages 
and CD4 positive T cells. During the 
inflammatory phase of EAM, Th1 cytokines (IL-
2, IFN-) and proinflammatory cytokines (IL-1, 
TNF-) are produced. The participation of TNF- 
in the pathogenesis of EAM has been clearly 
demonstrated. Administration of TNF- results in 
exacerbation of myocardial inflammation (33), 
while the functional blockade or suppression of 
TNF- production results in attenuation of 
cardiac inflammation (34, 35). The concentration 
of TNF- is elevated in patients with myocarditis 
(36). Our study showed that both serum levels and 
in vitro production of TNF- were significantly 
decreased in EAM animals treated with quercetin. 
These results support the possibility that quercetin 
ameliorates EAM by inhibiting the production of 
TNF- Previous findings that quercetin 
significantly inhibits TNF- production by human 
peripheral blood mononuclear cells and murine 
macrophages via modulation of NF-1 and I 
(24, 25) are in agreement with above assumption.  
We further assessed the influence of quercetin 
treatment on IL-10 production in EAM rats. IL-10 
is produced by Th2 cells and 
monocytes/macrophages, and is an antagonist of 
Th1 cytokines. In EAM hearts, IL-10 was mainly 
detected in non-cardiomyocytic non-inflammatory 
cells (mainly fibroblasts, smooth muscle cells, 
and endothelial cells) (37) and IL-10 targeting 
cells, which expressed IL-10 receptors, were 
mainly T cells expressing T cell antigen 
receptors (T cells) and CD11b+ cells 
(macrophages/dendritic cells/ granulocytes) (37, 
38). Several studies have demonstrated the 
therapeutic effect of IL-10 in myocarditis. 
Watanabe et al. showed that gene transfer of IL-
10 into muscle by electroporation in vivo was 
effective for the treatment of EAM (39). 
Administration of IL-10 attenuated myocardial 
inflammation and inhibited inducible NO 
synthase and the secretion of proinflammatory 
cytokines such as TNF-, IFN-, IL-2 and IL-12 
(40, 41). Here we showed that the level of IL-10 
in serum and also in supernatants of LNC was 
significantly higher in EAM rats treated with 
quercetin compared with vehicle-treated EAM 
rats. These results indicate that ameliorating 
effects of quercetin on EAM could be ascribed, at 
least in part, to up-regulation of IL-10 production. 
Recent data suggest that proinflammatory 
cytokine IL-17 plays an important role in 
pathogenesis of EAM (10, 13, 42). In mice, EAM 
development critically depends on the IL-23-
STAT4 axis that promotes the expansion of 
pathogenic IL-17 - producing Th17 subset (9). 
Adoptive transfer of myosin-specific CD4+ Th17 
cells induced autoimmune myocarditis in healthy 
mice (43) and treatment with antibodies to block 
IL-17 ameliorated disease severity in mice with 
ongoing EAM (10). Chang and colleagues proved 
the pathogenic role of IL-17 in the development 
of rat EAM (14). In the present study, we found 
that production of IL-17 by LNC was reduced in 
EAM rats treated with quercetin compared with 
vehicle-treated animals. These data indicate that 
quercetin ameliorated EAM, not only through the 
inhibition of production of TNF-, but also 
through suppression of IL-17. There was no 
significant difference in serum level of IL-17 
between quercetin- and vehicle-treated EAM 
animals. It is possible that immunomodulatory 
effect of quercetin on IL-17 production can only 
be detected in vitro or at the level of IL-17 mRNA 
in the myocardium. 
IL-12, produced by a variety of antigen-
presenting cells, including monocytes, 
macrophages, and dendritic cells, has been 
suggested to be involved in development of EAM 
as IL-12 (p40) and IL-12 receptor  knockouts 
are protected from disease (9, 44). However, more 
recently it became clear that the heterodimers IL-
12 (p40/35) and IL-23 (p40/p19) share the p40 
subunit and the  chain of their receptor and that 
IL-23, not IL-12 is essential for inflammatory 
heart disease (10). We demonstrated that 
quercetin did not influence the production of IL-
12 since neither serum level, nor production of 
this cytokine by LNC differed between quercetin- 
and vehicle-treated EAM animals. These results 
suggest that ameliorating effect of quercetin in 






EAM was not associated with inhibition of IL-12 
secretion. In line with our findings are previously 
reported data that IL-12 is not critical for EAM 
development (10). 
This study has some limitations. During our 
experiment, the drug treatment started at the same 
time with immunization of rats with the 
conclusion that quercetin reduced the severity of 
autoimmune myocarditis, while the onset process 
of the disease is usually advanced before 
administration of any drug to humans. We can not 
therefore extrapolate directly our results to 
humans and further investigations are needed 
before clinical use. 
In conclusion, from our data, quercetin 
reduced the severity of EAM and the mechanism 
of amelioration of the disease by this flavonoid 
could be ascribed to suppression of 
proinflammatory cytokines such as TNF- and 
IL-17 and up-regulation of IL-10. Therefore, it is 
anticipated that quercetin may be beneficial in 
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